Detroit's most storied nameplates once bottomed out in ways nobody saw coming.

A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...

Doug Wintemute is a staff writer for Forbes Advisor. After completing his master’s in English at York University, he began his writing career in the higher education space. Over the past decade, Doug ...